Health-related Quality of Life in a Prospective Study of Ultrasound to Detect Cystic Fibrosis-related Liver Disease in Children.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
8
9
2022
medline:
2
11
2022
entrez:
7
9
2022
Statut:
ppublish
Résumé
Cystic fibrosis liver disease (CFLD) begins early in life. Symptoms may be vague, mild, or nonexistent. Progressive liver injury may be associated with decrements in patient health before liver disease is clinically apparent. We examined Health-Related Quality of Life (HRQOL) in children enrolled in a multi-center study of CFLD to determine the impact of early CFLD on general and disease-specific QOL. Ultrasound (US) patterns of normal (NL), heterogeneous (HTG), homogeneous (HMG), or nodular (NOD) were assigned in a prospective manner to predict those at risk for advanced CFLD. Parents were informed of results. We assessed parent/child-reported (age ≥5 years) HRQOL by PedsQL 4.0 Generic Core and CF Questionnaire-revised (CFQ-R) prior to US and annually. HRQOL scores were compared by US pattern at baseline (prior to US), between baseline and 1 year and at 5 years. Multivariate analysis of variance (MANOVA) with Hotelling-Lawley trace tested for differences among US groups. Prior to US, among 515 participants and their parents there was no evidence that HTG or NOD US was associated with reduced PedsQL/CFQ-R at baseline. Parents of NOD reported no change in PedsQL/CFQ-R over the next year. Child-report PedsQL/CFQ-R (95 NL, 20 NOD) showed improvement between baseline and year 5 for many scales, including Physical Function. Parents of HMG children reported improved CFQ-R scores related to weight. Early undiagnosed or pre-symptomatic liver disease had no impact on generic or disease-specific HRQoL, and HRQoL was remarkably stable in children with CF regardless of liver involvement.
Identifiants
pubmed: 36070552
doi: 10.1097/MPG.0000000000003605
pii: 00005176-202211000-00016
pmc: PMC9624376
mid: NIHMS1833846
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
635-642Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK062453
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062456
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103149
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK062456
Pays : United States
Investigateurs
A Jay Freeman
(AJ)
Rene Romero
(R)
Adina L Alazraki
(AL)
Wikrom W Karnsakul
(WW)
Shruti M Paranjape
(SM)
Emily Dunn
(E)
Estella M Alonso
(EM)
Susanna McColley
(S)
Jennifer L Nicholas
(JL)
Joseph J Palermo
(JJ)
Assem G Ziady
(AG)
Alexander J Towbin
(AJ)
Michael R Narkewicz
(MR)
Roger K Harned
(RK)
Daniel H Leung
(DH)
Prakash Masand
(P)
Jean P Molleston
(JP)
Molly Bozic
(M)
Boaz W Karmazyn
(BW)
Sarah Jane Schwarzenberg
(SJ)
Glenn F Seidel
(GF)
Janis Stoll
(J)
Sakil Kulkarni
(S)
Marilyn Siegel
(M)
Nicole Green
(N)
Karen Murray
(K)
Randolph K Otto
(RK)
Simon C Ling
(SC)
Oscar M Navarro
(OM)
John C Magee
(JC)
Wen Ye
(W)
Edward Doo
(E)
Averell H Sherker
(AH)
Informations de copyright
Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
S.J.S. serves as a consultant for Nestle, UpToDate, and AbbVie. A.J.F. has grant/research support through Travere Therapeutics and Allergan; serves as an advisor for Abbvie and Takeda. W.K. has received research grants from Gilead Sciences and Albireo Pharma; serves as an advisor for Mirum and Travere Therapeutics. D.H.L. has grant/research support from Abbvie, Gilead, and Mirum; serves as a consultant for Gilead, Vertex, and Merck. S.C.L. receives research funding from Abbvie and Gilead and serves as a consultant for Abbvie JPM has research funding from Gillead, Abbvie, Albireo, Mirum. K.F.M. is a consultant for Albireo and Gilead. M.R.N. serves as a consultant for Vertex, has received research grants from Gilead, AbbVie, and has a family member with stock in Merck. The remaining authors report no conflicts of interest.
Références
Leung DH, Narkewicz MR. Cystic fibrosis-related cirrhosis. J Cyst Fibros. 2017;16:S50–61.
Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;302:1076–83.
Jardine J, Glinianaia SV, McConachie H, et al. Self-reported quality of life of young children with conditions from early infancy: a systematic review. Pediatrics. 2014;134:e1129–48.
Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246–56.e6.
Fredericks EM, Magee JC, Opipari-Arrigan L, et al. Adherence and health-related quality of life in adolescent liver transplant recipients. Pediatr Transplant. 2008;12:289–99.
Gulati R, Radhakrishnan KR, Hupertz V, et al. Health-related quality of life in children with autoimmune liver disease. J Pediatr Gastroenterol Nutr. 2013;57:444–50.
Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009;48:341–7.
Siegel MJ, Freeman AJ, Ye W, et al. Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease: interim results of a prospective observational case-controlled study. J Pediatr. 2020;219:62–69.e4.
Leung DH, Ye W, Molleston JP, et al. Baseline ultrasound and clinical correlates in children with cystic fibrosis. J Pediatr. 2015;167:862–868.e2.
Varni JW, Seid M, Knight TS, et al. The PedsQL 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making. J Behav Med. 2002;25:175–93.
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.
Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–39.
Quittner AL, Buu A, Messer MA, et al. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128:2347–54.
Quittner AL, Sawicki GS, McMullen A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res. 2012;21:1267–78.
Sedaghat AR. Understanding the Minimal Clinically Important Difference (MCID) of patient-reported outcome measures. Otolaryngol Head Neck Surg. 2019;161:551–60.
Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329–41.
Lenaerts C, Lapierre C, Patriquin H, et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr. 2003;143:343–50.
Abbott J, Morton AM, Hurley MA, et al. Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis. BMJ Open. 2015;5:e007418.
Abbott J, Hurley MA, Morton AM, et al. Longitudinal association between lung function and health-related quality of life in cystic fibrosis. Thorax. 2013;68:149–54.
van Horck M, Winkens B, Wesseling G, et al. Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up. Eur J Pediatr. 2017;176:1047–54.
Fernandez CV, Kodish E, Shurin S, et al. Offering to return results to research participants: attitudes and needs of principal investigators in the Children’s Oncology Group. J Pediatr Hematol Oncol. 2003;25:704–8.